Imo-8400

Published

dm+d

Unassigned

New Medicines

Psoriasis plaque

Information

Not Known
Idera Pharmaceuticals
Idera Pharmaceuticals

Development and Regulatory status

None
Discontinued
Discontinued
Mar 15: Idera pharmaceuticals reports they have discontinued the development of IMO 8400 for the treatment of plaque psoriasis as their focus is on dermatomyositis and Duchenne muscular dystrophy [1].

Category

Antisense-oligonucleotides
The prevalence of psoriasis is estimated to be about 1.3-2.2% in the UK, with the highest prevalence being in white people. [2]
Psoriasis plaque
Subcutaneous